| Autor: |
Michael P. Curry, Hugo E. Vargas, Alex S. Befeler, Nikolaos T. Pyrsopoulos, Vilas R. Patwardhan, Khurram Jamil |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Hepatology Communications, Vol 7, Iss 1, Pp e1307-e1307 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2471-254X |
| DOI: |
10.1097/01.HC9.0000897228.91307.0c |
| Popis: |
Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function. Liver transplantation remains the only curative treatment for decompensated cirrhosis. However, terlipressin, a vasopressin analog, successfully reverses HRS-1, and may improve patient survival while awaiting liver transplantation. Patients with higher baseline serum creatinine have a reduced response to treatment with terlipressin. These post hoc analyses examined pooled data from 352 patients with HRS-1 treated with terlipressin in 3 North American-centric, Phase III, placebo-controlled clinical studies (i.e. OT-0401, REVERSE, and CONFIRM)—across 3 serum creatinine subgroups (i.e. 5 mg/dL; p=0.01). Terlipressin-treated patients with HRS-1, with a lower baseline serum creatinine level, had a higher overall survival (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
